SCHEMBL25762140

SCHEMBL25762140

CC(C)NC(=O)/C(C#N)=C\C1CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.44
HPGD P15428 2/20 0.43
HTT P42858 1/20 0.43
MAPT P10636 6/20 0.42
KDM4E B2RXH2 4/20 0.42
KMT2A Q03164 4/20 0.42
MEN1 O00255 3/20 0.42
USP2 O75604 2/20 0.42
NPSR1 Q6W5P4 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.39
GAA P10253 1/20 0.39
IDE P14735 1/20 0.39
MAPK1 P28482 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
NEK2 P51955 1/20 0.36
LMNA P02545 1/20 0.34
ATM Q13315 1/20 0.34
TP53 P04637 1/20 0.34
BTK Q06187 1/20 0.33
STAT3 P40763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18559697 0.80 NEK2 (0.48) ALDH1A1MAPTKDM4EKMT2AMEN1
SCHEMBL18845456 0.79 ALDH1A1 (0.53) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL24091686 0.78 MEN1 (0.33) MAPTKMT2AMEN1NEK2
SCHEMBL18909667 0.78 MEN1 (0.33) MAPTKMT2AMEN1NEK2
SCHEMBL1318353 0.75 ALDH1A1 (0.55) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL1318351 0.75 ALDH1A1 (0.55) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL1318356 0.75 ALDH1A1 (0.55) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL1318355 0.75 ALDH1A1 (0.55) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL23722468 0.74 ALDH1A1 (0.49) ALDH1A1HPGDHTTMAPTKDM4E
SCHEMBL15804805 0.74 KMT2A (0.35) MAPTKMT2AMEN1NEK2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230212164-A1 ANNULATED 2-AMINO-3-CYANO THIOPHENES AND DERIVATIVES FOR THE TREATMENT OF CANCER RSU1, KRAS, NRAS ALDH1A1 2334/4885HPGD 4493/4885HTT 3923/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.